{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:15:09Z","timestamp":1780085709786,"version":"3.54.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10388-020-00765-2","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T15:04:02Z","timestamp":1596207842000},"page":"380-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association of residual gastric acid secretion with persistent symptoms in gastroesophageal reflux disease patients receiving standard-dose proton pump inhibitor therapy"],"prefix":"10.1007","volume":"18","author":[{"given":"H.","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shimodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Masamune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"765_CR1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","volume":"51","author":"K Iwakiri","year":"2016","unstructured":"Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751\u201367.","journal-title":"J Gastroenterol"},{"key":"765_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1365-2036.2010.04406.x","volume":"32","author":"H El-Serag","year":"2010","unstructured":"El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32:720\u201337.","journal-title":"Aliment Pharmacol Ther"},{"key":"765_CR3","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/gutjnl-2011-301897","volume":"61","author":"D Sifrim","year":"2012","unstructured":"Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61:1340\u201354.","journal-title":"Gut"},{"key":"765_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1572-0241.2005.41210.x","volume":"100","author":"S Charbel","year":"2005","unstructured":"Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005;100:283\u20139.","journal-title":"Am J Gastroenterol"},{"key":"765_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/dote.12293","volume":"29","author":"R Mandaliya","year":"2016","unstructured":"Mandaliya R, DiMarino AJ, Cohen S. Survey of findings in patients having persistent heartburn on proton pump inhibitor therapy. Dis Esophagus. 2016;29:27\u201333.","journal-title":"Dis Esophagus"},{"key":"765_CR6","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.3748\/wjg.v17.i14.1858","volume":"17","author":"M Sugimoto","year":"2011","unstructured":"Sugimoto M, Nishino M, Kodaira C, et al. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol. 2011;17:1858\u201365.","journal-title":"World J Gastroenterol"},{"key":"765_CR7","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1111\/j.1365-2036.2007.03529.x","volume":"26","author":"V Becker","year":"2007","unstructured":"Becker V, Bajbouj M, Waller K, et al. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors\u2014a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther. 2007;26:1355\u201360.","journal-title":"Aliment Pharmacol Ther"},{"key":"765_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00535-009-0070-6","volume":"44","author":"K Iwakiri","year":"2009","unstructured":"Iwakiri K, Kawami N, Sano H, et al. Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring. J Gastroenterol. 2009;44:708\u201312.","journal-title":"J Gastroenterol"},{"key":"765_CR9","doi-asserted-by":"publisher","first-page":"13352","DOI":"10.3748\/wjg.v21.i47.13352","volume":"21","author":"K Nakagawa","year":"2015","unstructured":"Nakagawa K, Koike T, Iijima K, et al. Characteristics of symptomatic reflux episodes in Japanese proton pump inhibitor-refractory non-erosive reflux disease patients. World J Gastroenterol. 2015;21:13352\u20139.","journal-title":"World J Gastroenterol"},{"key":"765_CR10","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.cgh.2013.10.026","volume":"12","author":"WO Rohof","year":"2014","unstructured":"Rohof WO, Bennink RJ, de Jonge H, et al. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2014;12:1647\u201355.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"765_CR11","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/ajg.2009.240","volume":"104","author":"A Gasiorowska","year":"2009","unstructured":"Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol. 2009;104:2005\u2013133.","journal-title":"Am J Gastroenterol"},{"key":"765_CR12","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1177\/2050640619880362","volume":"7","author":"W Januszewicz","year":"2019","unstructured":"Januszewicz W, Hartley J, Waldock W, et al. Endoscopic measurement of gastric pH associates with persistent acid reflux in patients treated with proton-pump inhibitors for gastroesophageal reflux disease. United Eur Gastroenterol J. 2019;7:1389\u201398.","journal-title":"United Eur Gastroenterol J"},{"key":"765_CR13","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/j.1572-0241.1998.00603.x","volume":"93","author":"K Iijima","year":"1998","unstructured":"Iijima K, Ohara S, Sekine H, et al. A new endoscopic method of gastric acid secretory testing. Am J Gastroenterol. 1998;93:2113\u20138.","journal-title":"Am J Gastroenterol"},{"key":"765_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/gut.46.1.20","volume":"46","author":"K Iijima","year":"2000","unstructured":"Iijima K, Ohara S, Sekine H, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut. 2000;46:20\u20136.","journal-title":"Gut"},{"key":"765_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00535-014-1031-2","volume":"50","author":"K Iijima","year":"2015","unstructured":"Iijima K, Koike T, Abe Y, et al. Time series analysis of gastric acid secretion over a 20-year period in normal Japanese men. J Gastroenterol. 2015;50:853\u201361.","journal-title":"J Gastroenterol"},{"key":"765_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/apt.12204","volume":"37","author":"C Jonasson","year":"2013","unstructured":"Jonasson C, Wernersson B, Hoff DA, et al. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;37:564\u201372.","journal-title":"Aliment Pharmacol Ther"},{"key":"765_CR17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/j.1365-2036.2004.01948.x","volume":"19","author":"K Iijima","year":"2004","unstructured":"Iijima K, Sekine H, Koike T, et al. Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. Aliment Pharmacol Ther. 2004;19:1181\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"765_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1620\/tjem.232.293","volume":"232","author":"K Iijima","year":"2014","unstructured":"Iijima K, Koike T, Abe Y, et al. Cutoff serum pepsinogen values for predicting gastric acid secretion status. Tohoku J Exp Med. 2014;232:293\u2013300.","journal-title":"Tohoku J Exp Med"},{"key":"765_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/apt.12007","volume":"36","author":"P Bytzer","year":"2012","unstructured":"Bytzer P, van Zanten SV, Mattsson H, et al. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis\u2014a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635\u201343.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"765_CR20","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1053\/j.gastro.2016.02.012","volume":"150","author":"Q Aziz","year":"2016","unstructured":"Aziz Q, Fass R, Gyawali CP, et al. Functional esophageal disorders. Gastroenterology. 2016;150(6):1368\u201379.","journal-title":"Gastroenterology"},{"key":"765_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1620\/tjem.235.249","volume":"235","author":"R Maejima","year":"2015","unstructured":"Maejima R, Koike T, Nakagawa K, et al. Esomeprazole inhibits the pentagastrin-stimulated secretion of gastric acid in healthy Japanese volunteers. Tohoku J Exp Med. 2015;235:249\u201353.","journal-title":"Tohoku J Exp Med"},{"issue":"Suppl 1","key":"765_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000200917","volume":"51","author":"NJ Bell","year":"1992","unstructured":"Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51(Suppl 1):59\u201367.","journal-title":"Digestion"},{"key":"765_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3109\/00365528609090908","volume":"118","author":"L Olbe","year":"1986","unstructured":"Olbe L, Lind T, Cederberg C, et al. Effect of omeprazole on gastric acid secretion in man. Scand J Gastroenterol Suppl. 1986;118:105\u20137.","journal-title":"Scand J Gastroenterol Suppl"},{"key":"765_CR24","first-page":"1527","volume":"91","author":"LP Leite","year":"1996","unstructured":"Leite LP, Johnston BT, Just RJ, et al. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol. 1996;91:1527\u201331.","journal-title":"Am J Gastroenterol"},{"key":"765_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1365-2036.2010.04358.x","volume":"32","author":"GE Boeckxstaens","year":"2010","unstructured":"Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2010;32:334\u201343.","journal-title":"Aliment Pharmacol Ther"},{"key":"765_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000456072","volume":"95","author":"S Hoshino","year":"2017","unstructured":"Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 2017;95:156\u201361.","journal-title":"Digestion"},{"key":"765_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000503340","volume":"2","author":"S Hamada","year":"2019","unstructured":"Hamada S, Ihara E, Ikeda H, et al. Clinical characterization of vonoprazan-refractory gastroesophageal reflux disease. Digestion. 2019;2:1\u20138. https:\/\/doi.org\/10.1159\/000503340.","journal-title":"Digestion"},{"key":"765_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gut.2007.133470","volume":"57","author":"F Zerbib","year":"2008","unstructured":"Zerbib F, Duriez A, Roman S, et al. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut. 2008;57:156\u201360.","journal-title":"Gut"},{"key":"765_CR29","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1053\/j.gastro.2017.07.017","volume":"153","author":"P Woodland","year":"2017","unstructured":"Woodland P, Shen Ooi JL, Grassi F, et al. Superficial esophageal mucosal afferent nerves may contribute to reflux hypersensitivity in nonerosive reflux disease. Gastroenterology. 2017;153:1230\u20139.","journal-title":"Gastroenterology"},{"key":"765_CR30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1365-2036.2004.02149.x","volume":"20","author":"C Gordon","year":"2004","unstructured":"Gordon C, Kang JY, Neild PJ, Maxwell JD. The role of the hiatus hernia in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:719\u201332.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-020-00765-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-020-00765-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-020-00765-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T23:37:40Z","timestamp":1627688260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-020-00765-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1007\/s10388-020-00765-2","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"25 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study protocol was approved by the Tohoku University Hospital Ethics Committee (2014-2-136), and all subjects provided their written informed consent prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}},{"value":"Masamune A received lecture fees from EA Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd, and received Commercial research funding from Otsuka Pharmaceutical Co., EA Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd.; Iijima K received lecture fees from Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and received Commercial research funding from Otsuka Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}